Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib-Reference-Cited by-同舟云学术

Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib

Published:2012-11-01 Issue:1 Volume:41 Page:230-237
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Wang Zhengping,Yang Jinfu,Kirk Christopher,Fang Ying,Alsina Melissa,Badros Ashraf,Papadopoulos Kyriakos,Wong Alvin,Woo Tina,Bomba Darrin,Li Jin,Infante Jeffrey R.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference27 articles.

1. RETRACTION: Hepatic CYP3A Suppression by High Concentrations of Proteasomal Inhibitors: A Consequence of Endoplasmic Reticulum (ER) Stress Induction, Activation of RNA-Dependent Protein Kinase-Like ER-Bound Eukaryotic Initiation Factor 2α (eIF2α)-Kinase (PERK) and General Control Nonderepressible-2 eIF2α Kinase (GCN2), and Global Translational Shutoff

2. A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

3. MG-132 inhibits the TCDD-mediated induction of Cyp1a1 at the catalytic activity but not the mRNA or protein levels in Hepa 1c1c7 cells

4. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

5. Development of proteasome inhibitors in oncology and autoimmune diseases;Bennett;Curr Opin Drug Discov Devel,2008

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium;Journal of Thrombosis and Haemostasis;2024-07

2. Brain-Permeable Immunoproteasome-Targeting Macrocyclic Peptide Epoxyketones for Alzheimer’s Disease;Journal of Medicinal Chemistry;2024-04-18

3. Proteasome Inhibitors in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer;Scientific Reports;2023-09-22

5. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09